Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccin...

by Kohli Michele, Lawrence Donna, Haig Jennifer, Anonychuk Andrea, Demarteau Nadia
Published 2012-10-01

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

by Merid Maraki, Bauch Chris T, Anonychuk Andrea M, Van Kriekinge Georges, Demarteau Nadia
Published 2009-10-01

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models

by Praditsitthikorn Naiyana, Kim Jane, Ginsberg Gary, Elbasha Elamin, Demarteau Nadia, Jit Mark, Sinanovic Edina, Hutubessy Raymond
Published 2011-05-01